Spaggiari Lorenzo, Magdeleinat Pierre, Kondo Haruhiko, Thomas Pascal, Leon Maria Elena, Rollet Gilles, Regnard Jean Francois, Tsuchiya Ryosuke, Pastorino Ugo
Department of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
Lung Cancer. 2004 Jun;44(3):339-46. doi: 10.1016/j.lungcan.2003.11.010.
The benefits of superior vena cava (SVC) resection for lung cancer remain controversial. Data obtained in four international centers were analyzed in order to identify prognostic factors and thus guide in future patient selection.
Retrospective study. Prognostic factors were examined by logistic regression for postoperative morbidity/mortality using the Kaplan-Meier method (log rank test) and the Cox proportional-hazard model for survival.
From 1963 to 2000, 109 patients underwent SVC resection. Induction treatment was given to 23 (21%) patients. The SVC was resected for T involvement in 78 (72%) cases and for N involvement in 31 (28%) cases. Fifty-five (50.5%) patients underwent pneumonectomy (20 with carinal resection), while the remaining underwent lobar resections. Prosthetic SVC replacement was performed in 28 (26%) patients; partial resection with running suture (53%), vascular stapler (13%), or patch (7%) was performed in 80 patients; 1 patient did not undergo reconstruction. Pathological examination identified direct involvement (T4) in 66 (60%) patients and N2 disease in 55 (50%) patients. Major postoperative morbidity and mortality were 30 and 12%, respectively. Median intensive care unit stay was 3 days, while median hospital stay was 16 days. Five-year survival was at 21%, with median survival at 11 months. In multiple regression analysis, induction treatment was associated with an increased risk of major complications (P = 0.016). None of the factors assessed demonstrated an association with postoperative death. In multivariate survival analysis, both pneumonectomy and complete resection of the SVC with prosthetic replacement were associated with a significant increased risk of death (P = 0.0013 and 0.014, respectively).
The radical resection of lung cancer involving the SVC may result in a permanent cure in carefully selected patients. The type of pulmonary resection (i.e., pneumonectomy) and the type of SVC resection (i.e., complete resection with prosthetic replacement) are the prognostic factors with the greatest adverse effect on survival.
上腔静脉(SVC)切除术治疗肺癌的益处仍存在争议。分析四个国际中心获取的数据,以确定预后因素,从而为未来的患者选择提供指导。
回顾性研究。采用Kaplan-Meier法(对数秩检验)通过逻辑回归分析术后发病率/死亡率的预后因素,采用Cox比例风险模型分析生存率的预后因素。
1963年至2000年,109例患者接受了SVC切除术。23例(21%)患者接受了诱导治疗。因肿瘤侵犯上腔静脉进行切除的有78例(72%),因淋巴结转移侵犯上腔静脉进行切除的有31例(28%)。55例(50.5%)患者接受了肺切除术(20例同时进行了隆突切除),其余患者接受了肺叶切除术。28例(26%)患者进行了人工血管置换上腔静脉;80例患者进行了部分切除并连续缝合(53%)、血管吻合器吻合(13%)或补片修补(7%);1例患者未进行重建。病理检查发现66例(60%)患者存在直接侵犯(T4),55例(50%)患者存在N2期疾病。术后主要发病率和死亡率分别为30%和12%。重症监护病房中位住院时间为3天,而医院中位住院时间为16天。五年生存率为21%,中位生存期为11个月。在多元回归分析中,诱导治疗与主要并发症风险增加相关(P = 0.016)。评估的因素均未显示与术后死亡相关。在多因素生存分析中,肺切除术和人工血管置换完全切除上腔静脉均与死亡风险显著增加相关(分别为P = 0.0013和0.014)。
对累及上腔静脉的肺癌进行根治性切除可能会使精心挑选的患者获得永久治愈。肺切除类型(即肺切除术)和上腔静脉切除类型(即人工血管置换完全切除)是对生存影响最大的预后因素。